Alby Elias1,2, Tia Cummins3, Regan Tyrrell1, Fiona Lamb1, Vincent Dore4, Robert Williams5, J V Rosenfeld6, Malcolm Hopwood2, Victor L Villemagne1, Christopher C Rowe1. 1. Department of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Victoria, Australia. 2. Department of Psychiatry, The University of Melbourne, Victoria, Australia. 3. The Florey Institute of Neuroscience and Mental Health. 4. CSIRO Brisbane, Queensland, Australia. 5. Melbourne Brain Centre, Parkville, Victoria, Australia. 6. Department of Neurosurgery, Monash University, Victoria, Australia.
Abstract
BACKGROUND: An association between obstructive sleep apnea (OSA) and Alzheimer's disease has been suggested but little is known about amyloid-β and tau deposition in this syndrome. OBJECTIVE: To determine amyloid and tau burden and cognitive function in OSA in comparison with those without a diagnosis of OSA. METHODS: The status of OSA was determined by asking participants about history of polysomnographic diagnosis of OSA and the use of Continuous Positive Airway Pressure (CPAP). A comprehensive neuropsychological battery measured cognitive function. Positron emission tomography (PET) was used to measure standardized uptake value ratio (SUVR) of 18F-florbetaben and 18F-AV1451, to quantify amyloid and tau burden. RESULTS: 119 male Vietnam veterans completed assessment. Impairment in visual attention and processing speed and increased body mass index (BMI) were seen in subjects with OSA compared with those without a diagnosis OSA. The cortical uptake of 18F-florbetaben was higher in the OSA group than in the control group (SUVR: 1.35±0.21 versus 1.27±0.16, p = 0.04). There were more apolipoprotein E ɛ4 allele (APOE ɛ4) carriers in the OSA group than in the control group. In multilinear regression analysis, the significance of OSA in predicting 18F-florbetaben uptake remained independent of age and vascular risk factors but not when BMI or APOE ɛ4 was adjusted. The reported use of CPAP (n = 14) had no effect on cognitive or amyloid PET findings. There was no significant difference in 18F-AV1451 uptake between the two groups. CONCLUSIONS: Obstructive sleep apnea is associated with Alzheimer's disease pathology, but this relationship is moderated by APOE ɛ4 and BMI.
BACKGROUND: An association between obstructive sleep apnea (OSA) and Alzheimer's disease has been suggested but little is known about amyloid-β and tau deposition in this syndrome. OBJECTIVE: To determine amyloid and tau burden and cognitive function in OSA in comparison with those without a diagnosis of OSA. METHODS: The status of OSA was determined by asking participants about history of polysomnographic diagnosis of OSA and the use of Continuous Positive Airway Pressure (CPAP). A comprehensive neuropsychological battery measured cognitive function. Positron emission tomography (PET) was used to measure standardized uptake value ratio (SUVR) of 18F-florbetaben and 18F-AV1451, to quantify amyloid and tau burden. RESULTS: 119 male Vietnam veterans completed assessment. Impairment in visual attention and processing speed and increased body mass index (BMI) were seen in subjects with OSA compared with those without a diagnosis OSA. The cortical uptake of 18F-florbetaben was higher in the OSA group than in the control group (SUVR: 1.35±0.21 versus 1.27±0.16, p = 0.04). There were more apolipoprotein E ɛ4 allele (APOE ɛ4) carriers in the OSA group than in the control group. In multilinear regression analysis, the significance of OSA in predicting 18F-florbetaben uptake remained independent of age and vascular risk factors but not when BMI or APOE ɛ4 was adjusted. The reported use of CPAP (n = 14) had no effect on cognitive or amyloid PET findings. There was no significant difference in 18F-AV1451 uptake between the two groups. CONCLUSIONS:Obstructive sleep apnea is associated with Alzheimer's disease pathology, but this relationship is moderated by APOE ɛ4 and BMI.
Entities:
Keywords:
Alzheimer’s disease; amyloid PET; dementia; obstructive sleep apnea; tau PET
Authors: Anna E Mullins; Korey Kam; Ankit Parekh; Omonigho M Bubu; Ricardo S Osorio; Andrew W Varga Journal: Neurobiol Dis Date: 2020-08-27 Impact factor: 5.996
Authors: Claire André; Stéphane Rehel; Elizabeth Kuhn; Brigitte Landeau; Inès Moulinet; Edelweiss Touron; Valentin Ourry; Gwendoline Le Du; Florence Mézenge; Clémence Tomadesso; Robin de Flores; Alexandre Bejanin; Siya Sherif; Nicolas Delcroix; Alain Manrique; Ahmed Abbas; Natalie L Marchant; Antoine Lutz; Olga M Klimecki; Fabienne Collette; Eider M Arenaza-Urquijo; Géraldine Poisnel; Denis Vivien; Françoise Bertran; Vincent de la Sayette; Gaël Chételat; Géraldine Rauchs Journal: JAMA Neurol Date: 2020-06-01 Impact factor: 18.302
Authors: Omonigho M Bubu; Ogie Q Umasabor-Bubu; Arlener D Turner; Ankit Parekh; Anna E Mullins; Korey Kam; Madeline K Birckbichler; Fahad Mukhtar; Alfred K Mbah; Natasha J Williams; David M Rapoport; Mony de Leon; Girardin Jean-Louis; Indu Ayappa; Andrew W Varga; Ricardo S Osorio Journal: Alzheimers Dement Date: 2020-10-08 Impact factor: 21.566
Authors: Diego Z Carvalho; Erik K St Louis; Christopher G Schwarz; Val J Lowe; Bradley F Boeve; Scott A Przybelski; Ashritha Reddy; Michelle M Mielke; David S Knopman; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: Neurology Date: 2020-03-26 Impact factor: 9.910